Teva Pharmaceuticals
TEVA
Market cap $19.3B

16.40 USD

-0.13

0.79%

At close Jul 11, 4:00 PM EDT

After hours

16.40

+0.00

0.00%

1 day

-0.79%

5 days

-3.70%

1 month

-5.31%

3 months

21.84%

6 months

-19.77%

Year to date

-23.00%

1 year

-4.09%

5 years

41.75%

10 years

-74.09%

About: Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Employees: 35,686

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

40% more call options, than puts

Call options by funds: $515M | Put options by funds: $369M

3.42% more ownership

Funds ownership: 58.66% [Q4 2024] → 62.08% (+3.42%) [Q1 2025]

4% more repeat investments, than reductions

Existing positions increased: 191 | Existing positions reduced: 183

4% less funds holding

Funds holding: 570 [Q4 2024] → 547 (-23) [Q1 2025]

18% less first-time investments, than exits

New positions opened: 70 | Existing positions closed: 85

26% less capital invested

Capital invested by funds: $14.7B [Q4 2024] → $10.9B (-$3.74B) [Q1 2025]

28% less funds holding in top 10

Funds holding in top 10: 36 [Q4 2024] → 26 (-10) [Q1 2025]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$22

34%

upside

Avg. target

$23

43%

upside

High target

$25

52%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

UBS Ashwani Verma	40%upside $23	Buy Maintained	26 Jun 2025
Goldman Sachs Matt Dellatorre	46%upside $24	Buy Initiated	6 Jun 2025
Truist Securities Les Sulewski	52%upside $25	Buy Initiated	28 May 2025
JP Morgan Chris Schott	40%upside $23	Overweight Upgraded	12 May 2025
B of A Securities Jason Gerberry	34%upside $22	Buy Maintained	8 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 9 articles about TEVA published over the past 30 days

Zacks Investment Research

TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?

TEVA stock jumps 21.6% in three months on branded drug growth, biosimilar launches, and margin-boosting cost cuts.

TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?

24/7 Wall Street

Billionaire Stanley Druckenmiller Sold Palantir And Buying This Stock Instead

Billionaire investment legend Stanley Druckenmiller is quickly becoming one of my favorite big-money managers to follow quarter to quarter.

Billionaire Stanley Druckenmiller Sold Palantir And Buying This Stock Instead

Teva Releases Q2 2025 Aide Memoire

TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the “Investors” page on its website.

Teva Releases Q2 2025 Aide Memoire

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday, July 30, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

The Motley Fool

Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?

Stanley Druckenmiller made a fortune working alongside billionaire George Soros. He ran his own hedge fund for years before closing it in 2010.

Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?

Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

TEL AVIV, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the final analysis of the pan-European PEARL Phase 4 migraine prevention study showed that AJOVY (fremanezumab), an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, delivered sustained effectiveness over a two-year period in reducing frequency, duration and severity of migraine attacks in patients with chronic and episodic migraine.1

Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine

Zacks Investment Research

Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy

TEVA teams up with Fosun to speed the development of TEV-56278, a novel anti-cancer immunotherapy targeting PD-1+ T cells.

Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278 Partnership leverages strategic relationships to enable research and development of innovative treatments to advance Teva's Pivot to Growth strategy TEL AVIV, Israel and SHANGHAI , June 16, 2025 /PRNewswire/ -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

The Motley Fool

Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters

There's nothing more valuable on Wall Street than data, and investors rarely have to dig to find something that's pertinent to the U.S. economy, the stock market, or their specific portfolio holdings.

Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters

Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Company Participants Richard D. Francis - President, CEO & Director Conference Call Participants Matthew Michael Dellatorre - Goldman Sachs Group, Inc., Research Division Matthew Michael Dellatorre Okay.

Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

See News Rankings

Charts implemented using Lightweight Charts™